Amivantamab, a bispecific epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with ulcerative intertrigo
Open Access
- 23 September 2025
- journal article
- case report
- Published by Elsevier in JAAD Case Reports
- Vol. 66, 12-14
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Amivantamab, the first epidermal growth factor receptor and mesenchymal–epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychiaJAAD Case Reports, 2024
- Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: A case seriesJAAD Case Reports, 2024
- Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?Cutis, 2023
- Spectrum of Dermatologic Adverse Events Associated With Amivantamab UseJAMA Dermatology, 2023
- Cutaneous adverse effects of biologic medicationsCleveland Clinic Journal of Medicine, 2020
- Granuloma Inframammary AdultorumJAMA Dermatology, 2014
- Erosive papulonodular dermatosis associated with topical benzocaine: A report of two cases and evidence that granuloma gluteale, pseudoverrucous papules, and Jacquet's erosive dermatitis are a disease spectrumJournal of the American Academy of Dermatology, 2006